Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of RNA and mRNA. The inventive solution exhibits a positive effect on stabilization of the nucleic acid (sequence) during lyophilization and storage but also leads to a considerable increase of the transfection efficiency of a nucleic acid. It thus also increases in vivo expression of a protein encoded by such a nucleic acid upon increased transfection rate. The present invention is furthermore directed to a method of lyophilization using the mannose-containing solution, to pharmaceutical compositions, vaccines, kits, first and second medical uses applying such a mannose-containing solution and/or a nucleic acid (sequence) lyophilized or resuspended with such a solution.
1. A lyophilized nucleic acid composition comprising, a plurality of mRNA molecules encoding a tumor or infectious disease antigen and a free, unconjugated and non-covalently bound mannose at a concentration of 0.5% (w/w) to 10% (w/w).
2. The lyophilized nucleic acid composition of claim 1 , wherein the residual water content of the lyophilized nucleic acid composition is reduced to a content of 0.5% (w/w) to 5% (w/w).
3. The lyophilized nucleic acid composition of claim 1 , wherein the lyophilized nucleic acid molecule has a relative integrity of at least about 70%.
4. The lyophilized nucleic acid composition of claim 1 , wherein the mRNA is complexed with a cationic or polycationic compound.
5. The lyophilized nucleic acid composition of claim 4 , wherein the mRNA is complexed with protamine.
6. The lyophilized nucleic acid composition of claim 1 , wherein the composition is free of DNA.
7. A solution comprising a plurality of mRNA molecules encoding a tumor or infectious disease antigen and a free, unconjugated and non-covalently bound mannose at a concentration of 0.5% (w/w) to 10% (w/w).
8. The solution of claim 7 , wherein the mannose concentration of the solution is in the range of 0.5 to 5% (w/w).
9. The solution of claim 7 , wherein the mRNA is complexed with a cationic or polycationic compound.
10. The solution of claim 9 , wherein the mRNA is complexed with protamine.
11. The solution of claim 7 , wherein the solution is free of DNA.
12. The solution of claim 7 , wherein the mannose is selected from α-D-Mannofuranose, β-D-Mannofuranose, α-D-Mannopyranose and β-D-Mannopyranose.
13. The solution of claim 7 , wherein the solution is present in an osmolarity in the range of about 200 mosmol/l to about 400 mosmol/l.
14. The solution of claim 7 , wherein the solution additionally comprises an isotonic buffer or its components selected from phosphate-buffered saline (PBS), TRIS-buffered saline (TBS), Hank's balanced salt solution (HBSS), Earle's balanced salt solution (EBSS), standard saline citrate (SSC), HEPES-buffered saline (FIBS), Grey's balanced salt solution (GBSS), normal saline (NaCl), and hypotonic (saline) solutions with addition of glucose or dextrose.
15. The solution of claim 7 , wherein the solution additionally comprises lactic acid.
16. The solution of claim 7 , wherein the solution additionally comprises an additive selected from the group consisting of mannite, polypeptides, amino acids, alcohols, carbohydrates, metals, metal ions, surfactants, polymers, complexing agents, and a buffer.
17. The solution of claim 15 , wherein the lactic acid is selected from the group consisting of L-(+)-lactic acid, (S)-lactic acid, D-(−)-lactic acid, (R)-lactic acid, and L-(+)-lactic acid, or a salt or an anion thereof.
18. The solution of claim 15 , wherein the lactic acid is selected from the group consisting of sodium-lactate, potassium-lactate, Al 3+ -lactate, NH 4+ -lactate, Fe-lactate, Li-lactate, Mg-lactate, Ca-lactate, Mn-lactate and Ag-lactate.
19. The solution of claim 7 , wherein the solution comprises Ringer's lactate (RiLa), acetated Ringer's solution, lactate containing water or ortholactate-containing solutions.
20. The solution of claim 10 , wherein the solution is free of DNA and the mRNA is complexed with protamine.